Glenmark Specialty, Hikma Pharma launch seasonal allergic rhinitis nasal spray in US
|
Overview
Hikma Pharmaceuticals PLC, the multinational pharmaceutical company, and Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals Ltd. have announced the launch of RYALTRIS (olopatadine hydrochloride and mometasone furoate nasal spray) in the US.
RYALTRIS is approved by the US Food and Drug Administration (USFDA) for the treatment of symptoms of seasonal allergic rhinitis (SAR) in adult and pediatric patients 12 years of age and older.
For more details, check out the link given below:
Glenmark specialty, Hikma pharma launch seasonal allergic rhinitis nasal spray RYALTRIS in US
Speakers
Roshni Dhar, a Mass com graduate with a soft corner for health happenings, joined Medical Dialogues as a news anchor in 2021. Inspired by her mother who is a gynaecologist, she likes to keep herself and the world updated on the occurring in the medical field. She covers various aspects of health news for MDTV at Medical Dialogues. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751
